These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

717 related items for PubMed ID: 18423977

  • 1. The role of the digital rectal examination in subsequent screening visits in the European randomized study of screening for prostate cancer (ERSPC), Rotterdam.
    Gosselaar C, Roobol MJ, Roemeling S, Schröder FH.
    Eur Urol; 2008 Sep; 54(3):581-8. PubMed ID: 18423977
    [Abstract] [Full Text] [Related]

  • 2. Digital rectal examination and the diagnosis of prostate cancer--a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam.
    Gosselaar C, Roobol MJ, van den Bergh RC, Wolters T, Schröder FH.
    Eur Urol; 2009 Jan; 55(1):139-46. PubMed ID: 18406045
    [Abstract] [Full Text] [Related]

  • 3. Screening for prostate cancer at low PSA range: the impact of digital rectal examination on tumor incidence and tumor characteristics.
    Gosselaar C, Roobol MJ, Roemeling S, van der Kwast TH, Schröder FH.
    Prostate; 2007 Feb 01; 67(2):154-61. PubMed ID: 17044079
    [Abstract] [Full Text] [Related]

  • 4. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ, van der Cruijsen IW, Schröder FH.
    Urology; 2004 May 01; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [Abstract] [Full Text] [Related]

  • 5. Characteristics of prostate cancer detected by digital rectal examination only.
    Okotie OT, Roehl KA, Han M, Loeb S, Gashti SN, Catalona WJ.
    Urology; 2007 Dec 01; 70(6):1117-20. PubMed ID: 18158030
    [Abstract] [Full Text] [Related]

  • 6. Repeat prostate biopsy in the prostate, lung, colorectal and ovarian cancer screening trial.
    Pinsky PF, Crawford ED, Kramer BS, Andriole GL, Gelmann EP, Grubb R, Greenlee R, Gohagan JK.
    BJU Int; 2007 Apr 01; 99(4):775-9. PubMed ID: 17223921
    [Abstract] [Full Text] [Related]

  • 7. Percent free PSA as an additional measure in a prostate cancer screen.
    Miele ME.
    Clin Lab Sci; 2001 Apr 01; 14(2):102-7. PubMed ID: 15625982
    [Abstract] [Full Text] [Related]

  • 8. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP, Zhu X, Bul M, Bangma CH, Schröder FH, Roobol MJ.
    BJU Int; 2012 Dec 01; 110(11):1654-60. PubMed ID: 23043563
    [Abstract] [Full Text] [Related]

  • 9. Digital rectal examination is barrier to population-based prostate cancer screening.
    Nagler HM, Gerber EW, Homel P, Wagner JR, Norton J, Lebovitch S, Phillips JL.
    Urology; 2005 Jun 01; 65(6):1137-40. PubMed ID: 15922431
    [Abstract] [Full Text] [Related]

  • 10. Prostate cancer in patients with an abnormal digital rectal examination and serum prostate-specific antigen less than 4.0 ng/mL.
    Bozeman CB, Carver BS, Caldito G, Venable DD, Eastham JA.
    Urology; 2005 Oct 01; 66(4):803-7. PubMed ID: 16230142
    [Abstract] [Full Text] [Related]

  • 11. The value of different screening tests in predicting prostate biopsy outcome in screening for prostate cancer data from a multicenter study (ERSPC).
    Roobol MJ, Zappa M, Määttänen L, Ciatto S.
    Prostate; 2007 Mar 01; 67(4):439-46. PubMed ID: 17192912
    [Abstract] [Full Text] [Related]

  • 12. Prostate cancer screening within a prostate specific antigen range of 3 to 3.9 ng./ml.: a comparison of digital rectal examination and free prostate specific antigen as supplemental screening tests.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    J Urol; 2001 Oct 01; 166(4):1339-42. PubMed ID: 11547069
    [Abstract] [Full Text] [Related]

  • 13. [Screening of cancer of the prostate: study in a Spanish population].
    Herrero Payo JA, Montes Díaz MJ, Páez Borda A, Sánchez Sánchez E, Moreno Valle JA, Berenguer Sánchez A.
    Arch Esp Urol; 1996 Oct 01; 49(6):595-606. PubMed ID: 8929102
    [Abstract] [Full Text] [Related]

  • 14. Prostate-specific antigen velocity at low prostate-specific antigen levels as screening tool for prostate cancer: results of second screening round of ERSPC (ROTTERDAM).
    Roobol MJ, Kranse R, de Koning HJ, Schröder FH.
    Urology; 2004 Feb 01; 63(2):309-13; discussion 313-5. PubMed ID: 14972478
    [Abstract] [Full Text] [Related]

  • 15. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer.
    Gosselaar C, Kranse R, Roobol MJ, Roemeling S, Schröder FH.
    Prostate; 2008 Jun 15; 68(9):985-93. PubMed ID: 18409186
    [Abstract] [Full Text] [Related]

  • 16. Detection rate of prostate cancer according to prostate-specific antigen and digital rectal examination in Korean men: a nationwide multicenter study.
    Seo HK, Chung MK, Ryu SB, Lee KH, Korean Urological Oncologic Society Prostate Cancer Study Group.
    Urology; 2007 Dec 15; 70(6):1109-12. PubMed ID: 18158028
    [Abstract] [Full Text] [Related]

  • 17. A multicenter study on the detection of prostate cancer by digital rectal examination and prostate-specific antigen in men with or without urinary symptoms. Cooperative Group for Diagnosis of Prostate Cancer.
    Eur Urol; 1997 Dec 15; 32(2):133-9. PubMed ID: 9286642
    [Abstract] [Full Text] [Related]

  • 18. Screening for prostate cancer.
    Pode D, Shapiro A, Lebensart P, Meretyk S, Katz G, Barak V.
    Isr J Med Sci; 1995 Dec 15; 31(2-3):125-8. PubMed ID: 7538101
    [Abstract] [Full Text] [Related]

  • 19. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
    Schröder FH, Bangma CH, Roobol MJ.
    Eur Urol; 2008 May 15; 53(5):901-8. PubMed ID: 18262712
    [Abstract] [Full Text] [Related]

  • 20. [Screening for early detection of prostate cancer (first experience in Israel)].
    Neheman A, Shotland Y, Metz Y, Stein A.
    Harefuah; 2001 Jan 15; 140(1):4-10, 88, 87. PubMed ID: 11242898
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 36.